RESEARCH TRIANGLE PARK, NC -- (Marketwire) -- 11/21/08 -- A recently published therapeuticarea forecasting report from pharmaceutical business intelligence leaderCutting Edge Information finds that DPP-4 inhibitors will quickly becomethe highest-grossing class within the diabetes market, even outpacing thelong-acting insulins.The DPP-4 class entered the market in 2006 when Merck won approval tomarket Januvia. The class has three distinct advantages setting it apartfrom competitors: a lowered risk for hypoglycemia, a lowered risk forweight gain, and an oral formulation. Though Januvia remains the onlyFDA-approved DPP-4 inhibitor, two rivals are racing through development,and both are expected to reach blockbuster status.
"With health scares linked to TZDs and GLP-1 analogs, the DPP-4 class hasbecome a lucrative research target within the diabetes field," says leadauthor Jeremy Spivey. "Januvia will likely become the top-selling Type IIdiabetes drug by 2012, and other companies are eager to produce DPP-4s oftheir own."
"Diabetes Market Forecast to 2013"(http://cuttingedgeinfo.com/Diabetes/index.htm) examines trends affectingthe diabetes space today and their impact leading into the next decade. Itdetails the historical, current and forecasted performance of more than 50drugs -- including marketed brands, pipeline products and those still indevelopment -- treating diabetes and its complications, as well asanalyzing the top seven drug makers in the diabetes market.
The report breaks diabetes data down by individual drug, class, andcompany; and it identifies which drug classes have the most potential in ahighly competitive market. The structure leads to data comparisons andanalyses across multiple levels, and enables an honest appraisal of keydevelopments facing players in the diabetes space.
Brand and drug manufacturer profiles are also included. Brand profilesdetail a product's competitive and strategic positioning, marketopportunities, and patent and litigation status.
Profiles include the following information:
-- Drug's current and projected competitive strength-- Current/projected sales position within drug class-- Sales projection charts for the next four to seven years-- Competitive assessment-- Clinical trial information
Company profiles analyze seven companies with the top diabetes franchisesor exciting development pipelines. Profiles contain:
-- Company ranking in diabetes market-- Overall industry ranking-- Strengths analysis-- Growth areas analysis-- Competition analysis-- Key products breakdown
Learn more about the report and download a brochure athttp://cuttingedgeinfo.com/Diabetes/index.htm
Add to Digg Bookmark with del.icio.us Add to Newsvine
CONTACT INFORMATION:
Jeremy Spivey
Email Contact
919-433-0373
